Adjusted analyses associated overestimation with nearly doubled 2-year mortality (aHR 1.98; 95% CI, 1.04-3.77). Differences in advanced-therapy receipt did not explain the mortality signal, suggesting ...

Heart failure (HF) substantially impacts the health and financial security of an increasing proportion of the US population. It worsens debility and quality of life and may lead to hospitalization and ...

—These study results support the use of a remote, algorithm-based, navigator-led titration strategy to optimize the management of patients with heart failure with reduced ejection fraction (HFrEF).

"These findings suggest that small variations in the amount of fluid given to a patient with sepsis, or the decision to give less fluid to a patient because they have heart failure, may not have a ...

Please provide your email address to receive an email when new articles are posted on . “The EMPEROR-Reduced trial required patients to be treated for heart failure, but did not mandate specific doses ...

Human heart, computer artwork. Despite an increasing emphasis on HFmrEF over the past several years, there is a lack of authoritative guidance surrounding therapeutic approaches for these patients.

Credit: Getty Images. The approval was based on data from the phase 3 EMPEROR-Reduced trial. The Food and Drug Administration (FDA) has approved Jardiance ® (empagliflozin) to reduce the risk of ...

INGELHEIM, Germany and INDIANAPOLIS--(BUSINESS WIRE)--Full results from the EMPEROR-Reduced Phase III trial in adults with heart failure with reduced ejection fraction, with and without diabetes, ...

Human heart, computer artwork. Despite an increasing emphasis on HFmrEF over the past several years, there is a lack of authoritative guidance surrounding therapeutic approaches for these patients.